AKT1 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 3 clinical trials for small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and small cell lung carcinoma as inclusion criteria, 3 are phase 1/phase 2 (3 open) [3].

ATM is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATM status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

ATR is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BAP1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BAP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BARD1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BLM is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

BRAF is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is an inclusion eligibility criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRIP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 4 clinical trials for small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain CDK12 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [3].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CHEK1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CHEK1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

CHEK2 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain CHEK2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 4 clinical trials for small cell lung carcinoma, of which 4 are open and 0 are closed. Of the trials that contain EGFR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ERBB2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCB is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCB status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCC is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCC status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCD2 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCD2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCE is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCE status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCF is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCF status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCG is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCG status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCI is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCI status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCL is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCL status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FANCM is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain FANCM status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MCPH1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain MRE11A status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MYCL is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYCL status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

MYCN is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

NBN is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain NBN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PALB2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 3 clinical trials for small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PDGFRA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRB status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PPP2R2A status and small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

PTEN is an inclusion eligibility criterion in 7 clinical trials for small cell lung carcinoma, of which 5 are open and 2 are closed. Of the trials that contain PTEN status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (4 open), and 2 are phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD50 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51B is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51B status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51C is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51C status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD51D is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD51D status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RAD52 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD52 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RAD54L is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD54L status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

RECQL4 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RECQL4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RICTOR is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RICTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RPA1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain SLX4 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

STK11 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 2 clinical trials for small cell lung carcinoma, of which 0 are open and 2 are closed. Of the trials that contain TP53 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains VEGFA status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains VEGFB status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

WRN is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains WRN status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].